Du är här


FIT Biotech Oy: The Board of Directors of FIT Biotech Decides on Conversion of Shares

Company Release, September 8, 2015 at 15.00 EET

The Board of Directors of FIT Biotech Decides on Conversion of Shares

Today, the board of directors of FIT Biotech Oy (the 'Company') decided on the
conversion of shares representing different series of shares in the Company
in accordance with the conversion commitment submitted by the shareholder to
the Company.

The board decided on the conversion of 3,000 D shares into K shares in
accordance with section 5 of the Company's articles of association (1:1).
After the conversion, the Company will have 27,599,817 K shares, 5,229 A
shares and 65,235 D shares. The total number of shares in the Company,
27,670,281, is not affected by the conversion.

The Company's K shares are traded under the trading symbol FITBIO on the
multilateral First North market maintained by the Helsinki Stock Exchange.

The date of entry in the Trade Register of the converted K shares and the
first trading date of the converted K shares on First North will be announced

Board of Directors

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy

Phone: +358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:

FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA
vaccines and gene therapy. The company bases its products on its patented GTU
® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech
develops DNA vaccines in order to both prevent and also treat various
diseases. Identified application areas include HIV, tuberculosis (and other
infectious diseases) as well as gene therapy (cancer, autoimmune diseases).
Other application areas are under development. FIT Biotech Oy is listed on
NASDAQ First North (ticker: FITBIO). More information can be found

Major media


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.